Significance of the potential role of pharmacological MRI (phMRI) in diagnosis of Parkinson’s disease

Abstract

The initial diagnosis of Parkinson’s disease (PD) is currently based on a clinical assessment. Many patients who receive an initial diagnosis of PD have parkinsonian features related to other diseases such as essential tremor, vascular parkinsonism and atypical parkinsonian disorder. It has been challenging to differentiate PD from those disorders, especially in the early disease stages, due to an overlap of clinical signs and symptoms. Therefore, there is a great need for development of noninvasive, highly sensitive, and widely available imaging methods that can potentially be used to assistant physicians to make more accurate diagnosis of the disease; and to longitudinally monitor treatment of PD. Recent advance of pharmacological MRI (phMRI) technology allows non-invasively mapping functional stages for nigrostriatal dopamine (DA) system. This article aims to review research findings primarily from our group in nonhuman primates modeling the neurodegenerative disease on the value of phMRI techniques in the diagnosis of PD.

Keywords

pharmacological MRI (phMRI) / Parkinson’s disease / phMRI techniques

References

[1] Andersen A H, Zhang Z, Barber T, Rayens W S, Zhang J, Grondin R, Hardy P, Gerhardt G A, Gash D M (2002). Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies. J Neurosci Methods, 118(2): 141-152

[2] Arthurs O J, Boniface S (2002). How well do we understand the neural origins of the fMRI BOLD signal? Trends Neurosci, 25(1):27-31

[3] Braak H, Del Tredici K (2008). Cortico-basal ganglia-cortical circuitry in Parkinson’s disease reconsidered. Exp Neurol, 212(1): 226-229

[4] Chen Q, Andersen A H, Zhang Z, Ovadia A, Gash D M, Avison M J (1996). Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. Magn Reson Imaging, 14(5): 469-476

[5] Chin C L, Tovcimak A E, Hradil V P, Seifert T R, Hollingsworth P R, Chandran P, Zhu C Z, Gauvin D, Pai M, Wetter J, Hsieh G C, Honore P, Frost J M, Dart M J, Meyer M D, Yao B B, Cox B F, Fox G B (2008). Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol, 153(2): 367-379

[6] Ding F, Luan L, Ai Y, Walton A, Gerhardt G A, Gash D M, Grondin R, Zhang Z (2008). Development of a stable, early stage unilateral model of Parkinson’s disease in middle-aged rhesus monkeys. Exp Neurol, 212(2): 431-439

[7] Fearnley J M, Lees A J (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 114(5): 2283-2301

[8] Honey G, Bullmore E (2004). Human pharmacological MRI. Trends Pharmacol Sci, 25(7): 366-374

[9] Jenkins B G, Sanchez-Pernaute R, Brownell A L, Chen Y C, Isacson O (2004). Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J Neurosci, 24(43): 9553-9560

[10] Langston J W, Ballard P A Jr (1983). Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med, 309(5): 310-321

[11] Nguyen T V, Brownell A L, Iris Chen Y C, Livni E, Coyle J T, Rosen B R, Cavagna F, Jenkins B G (2000). Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse, 36(1): 57-65

[12] Nicklas W J, Youngster S K, Kindt M V, Heikkila R E (1987). MPTP, MPP⁺ and mitochondrial function. Life Sci, 40(8): 721-729

[13] Pavese N, Brooks D J (2009). Imaging neurodegeneration in Parkinson’s disease. Biochim Biophys Acta, 1792(7): 722-729

[14] Rasmussen I Jr (2010). Psychopharmacological MRI. Acta Neuropsychiatr, 22(1): 38-39

[15] Richardson J R, Caudle W M, Guillot T S, Watson J L, Nakamaru-Ogiso E, Seo B B, Sherer T B, Greenamyre J T, Yagi T, Matsuno-Yagi A, Miller G W (2007). Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci, 95(1): 196-204

[16] Thiel C M (2009). Neuropharmacological fMRI. Neuropharmakologisches fMRT, 40: 233-238

[17] Tracey I (2001). Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol, Suppl: 21S-28S

[18] Wu Y, Le W, Jankovic J (2011). Preclinical biomarkers of Parkinson disease. Arch Neurol, 68(1): 22-30

[19] Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G, Gash D (2001). Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage, 14(5): 1159-1167

[20] Zhang Z, Andersen A H, Ai Y, Loveland A, Hardy P A, Gerhardt G A, Gash D M (2006). Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage, 33, 636-643

[21] Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G, Gash D (2001). Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage, 14(5): 1159-1167

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg